CVS Health on Wednesday reported that it's been hit hard by higher medical costs. It led the company to slash its full-year ...
The Covid-era swagger is gone. The cost cuts are mostly done. The executives are “cautiously optimistic.” And the ...
For biosimilars to win, AbbVie has to lose, according to Boehringer Ingelheim. The German drugmaker on Wednesday said that ...
Sen. Maggie Hassan (D-NH) is pressuring GSK to put a commonly used pediatric inhaler back on the market after the company stopped producing it in late 2023 in favor of an authorized generic version.
Senators questioned UnitedHealth Group CEO Andrew Witty for more than two hours on Tuesday over the February cyberattack that paralyzed the US healthcare industry for months and bled some providers ...
GSK wants to present Blenrep to regulatory bodies sooner. The UK pharma will submit Blenrep in second-line multiple myeloma ...
Neurocine Biosciences won FDA approval on Tuesday for a new formulation that may help Ingrezza go down in a more delightful ...
The new round of letters targets 20 products and follows a push by the FTC last year to go after patents on asthma ...
Novartis is looking to build on its radiopharma research machinery. The maker of Lutathera and Pluvicto has expanded its ...
Real Chemistry plans to harness the “Wild West” of GLP-1 social media and reams of competitive data in the drug category with ...
UnitedHealth Group's CEO Andrew Witty is set to testify before lawmakers on Wednesday to explain how the company handled ...
Moderna is inviting LinkedIn and Instagram scrollers to take a break with its scientists in a Coffee Break Science series that started this week. The short videos lead off with infectious disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results